Circulating levels of small molecules or metabolites are highly heritable, but the impact of 54 genetic differences in metabolism on human health is not well understood. In this cross-platform, 55 genome-wide meta-analysis of 174 metabolite levels across six cohorts including up to 86,507 56 participants (70% unpublished data), we identify 499 (362 novel) genome-wide significant 57 associations (p<4.9×10 -10 ) at 144 (94 novel) genomic regions. We show that inheritance of blood 58 metabolite levels in the general population is characterized by pleiotropy, allelic heterogeneity, rare 59 and common variants with large effects, non-linear associations, and enrichment for 60 nonsynonymous variation in transporter and enzyme encoding genes. The majority of identified 61 genes are known to be involved in biochemical processes regulating metabolite levels and to cause 62 monogenic inborn errors of metabolism linked to specific metabolites, such as ASNS (rs17345286, 63 MAF=0.27) and asparagine levels. We illustrate the influence of metabolite-associated variants on 64 human health including a functional variant (rs17681684) in GLP2R associated with citrulline levels, 65 impaired insulin secretion and type 2 diabetes risk. We link genetically-higher serine levels to a 95% 66 reduction in the likelihood of developing macular telangiectasia type 2 [odds ratio (95% confidence 67 interval) per standard deviation higher levels 0.05 (0.03-0.08; p=9.5×10 -30 )]. We further demonstrate 68 the predictive value of genetic variants identified for serine or glycine levels for this rare and difficult 69 to diagnose degenerative retinal disease [area under the receiver operating characteristic curve:
Introduction

77
Metabolites are small molecules that reflect biological processes and are widely measured in 78 clinical medicine as diagnostic, prognostic or treatment response biomarkers 1 . Blood levels of 79 metabolites are highly heritable as shown by previous studies which attempted to characterise the In 61 of the 499 associations the lead association signal was a nonsynonymous variant, a 40-fold 178 enrichment compared to what would be expected by chance given the annotation of ascertained 179 genetic variants (two-tailed binomial test, p=5×10 -30 , Fig. 3D ). For a further 59 associations, the lead 180 variant was in high LD with a nonsynonymous variant (R 2 >0.8). Lead variants that were 181 nonsynonymous, or variants in high LD with a nonsynonymous variant, generally had lower MAF and 182 larger effect sizes than variants that were not in these categories (Fig 3B-C) . 
193
We identified 22 loci harbouring two (n=21) or three (n=1) independent signals, i.e. different 194 plasma metabolites were associated with distinct genetic variants within the same genomic region 195 ( Supplementary Table S2 ). For six regions our two different annotations approaches assigned only 196 one causal gene (see below and Methods), including ACADM, GLDC, ARG1, MARCH8, SLC7A2, and 197 LIPC ( Supplementary Table S2 ). We found evidence that allelic heterogeneity, i.e. conditionally 198 independent variants at a locus for a specific metabolite, explains the association pattern at 3 of 199 those loci (ACADM, ARG1, and LIPC; Supplementary Table S4 ). We identified another 16 loci 200 7 harbouring at least one (range: 2-6) additional conditionally independent variant(s) in exact 201 conditional analyses (see Methods, Supplementary Table S4 ).
203
Effector genes, tissues, pathways 204 We used two complementary strategies to prioritize likely causal genes for the observed 205 associations: (1) a hypothesis-free genetic approach based on physical distance, genomic annotation 206 and integration of expression quantitative trait loci (eQTLs) to prioritize genes in a systematic and 207 standardised way (see Methods), and (2) a biological knowledge-based approach integrating existing 208 knowledge about specific metabolites or related pathways to identify biologically plausible 209 candidate genes from the 20 genes closest to the lead variant ( Fig. 4A) . Using the hypothesis-free 210 genetic approach, we identified 249 unique likely causal genes for the 499 associations, with at least 211 one gene per association and some genes prioritized as likely causal for multiple metabolite 212 associations. The knowledge-based approach identified 130 biologically plausible genes for 349 out 213 of 499 associations. We asked whether the hypothesis-free genetic approach identified biologically 214 plausible genes (prioritized by strategy 2) more often than expected by chance. An excess of 215 biologically plausible genes amongst those prioritized by the hypothesis-free genetic algorithm 216 would suggest that the approach is able to prioritize true positive associations that map to known 217 pathways or underlying biology. Amongst 9,980 genes screened at the 499 associations, 420 (4.2%) 218 were biologically plausible. A total of 350 gene-metabolite assignments from the first approach were 219 also annotated in the knowledge-based approach with 126 pairs (36%) termed biologically plausible 220 (~8-fold more than expected by chance; two-tailed binomial test, p=2.3×10 -80 ; Fig. 4B ). Among the 221 consistently assigned genes between both approaches assignment of the nearest gene (124 times 222 out of 126, Χ 2 -test, p<2.5x10 -45 ) was the strongest shared factor, as might be expected, followed by 223 presence of a missense variant at least in LD (R 2 >0.8, 30 times out of 126, Χ 2 -test, p<1.3x10 -07 ) and 224 only a minor contribution of eQTL data (20 times out of 126, Χ 2 -test, p<0.001). Over 70% of 225 genetically prioritized genes were enzymes or transporters ( Fig. 4C) .
226
In addition to being enriched in genes previously implicated in the biology of these metabolites,
227
the genetically prioritized genes were also enriched in genes known for mutations to cause rare 
239
Integrating GWAS statistics across cohorts and platforms allowed us to identify three genes that 240 have never been associated with any metabolite level so far. At the CERS6 locus, rs4143279 241 associates with levels of sphingomyelin (d18:1/16:0)) (p = 4.2x10 -10 ). CERS6 encodes a ceramide 242 synthase facilitating formation of ceramide, a precursor of sphingomyelins 15 . At the ASNS locus, 243 rs17345286 associates with levels of asparagine (p = 4.7x10 -20 ). The lead variant is in high LD (R 2 =1) 244 with a missense mutation in ASNS (rs1049674, p.Val210Glu). ASNS encodes an asparagine 245 synthase 16 . Finally, at the SLC43A1 locus, rs2649667 associates with levels of phenylalanine (p = 246 3.6x10 -13 ). SLC43A1 encodes a liver-enriched transporter of large neutral amino acids, including 247 phenylalanine 17 .
248
Insights into the causes of common and rare diseases from metabolite-associated loci
249
The phenotypic consequences of metabolite-associated variants are currently not well 250 characterized. Here, we systematically investigate the contribution of individual loci and polygenic 251 predisposition associated with differences in metabolite levels to the risk of common and rare 252 diseases.
253
A citrulline-raising functional variant in GLP2R increases type 2 diabetes risk 254 Because several of the metabolites captured in this GWAS have been associated with incident 255 type 2 diabetes, we sought to investigate whether the association between metabolite-associated 256 9 loci and diabetes could provide insights into underlying pathophysiologic mechanisms. Using 257 estimates of effect for association with type 2 diabetes based on a meta-analysis of 80,983 cases and 258 842,909 controls (see Methods), we observed a significant enrichment for associations with type 2 259 diabetes (p-value=2.8x10 -7 ) of metabolite-associated variants compared to a matched control set of 260 variants (Fig. 5A) .
261
Amongst the diabetes-and metabolite-associated loci was a missense p.Asp470Asn
262
(rs17681684) variant in the GLP2R gene encoding the receptor for glucagon-like peptide 2, a 33 263 amino acid peptide hormone encoded by the proglucagon gene (GCG) that stimulates the growth of 264 intestinal tissue. Common variants at GLP2R are associated with an increased risk of type 2 diabetes 265 (T2D) and lower levels of insulin secretion 18 . The previously reported lead variant for T2D 266 (rs78761021) is in high LD (0.87) with our lead citrulline association signal at GLP2R (rs17681684),
267
which was associated with a 4% higher type 2 diabetes risk (per-allele odds ratio, 1.04; 95% 268 confidence interval, 1.02, 1.05; p=1.1×10 -08 ), comparable to previous reports 18 . Our results show that 269 the genetic signal for association with T2D statistically colocalises (posterior probability=0.94) with 270 that for citrulline ( Fig. 5B) , levels of which reflect the volume of intestinal cells and are a marker of 271 GLP2R target engagement in the treatment of short-bowel syndrome with glucagon-like peptide 2 272 analogues 19 . The GLP2R p.Asp470Asn variant was the only of 6 independent genome-wide significant 273 citrulline-raising loci that was associated with a higher risk of type 2 diabetes, which indicates that 274 the association does not reflect a general impact of citrulline levels on diabetes risk but rather a 275 locus-specific association at GLP2R (Fig. 5C ). Taken together, this suggests that genetically higher 276 GLP2R signalling, indicated by the higher citrulline levels among GLP2R 470Asn carriers, is associated 277 with an increased risk of diabetes via lower insulin secretion. 
282
We show that the variant allele is significantly associated with reduced recruitment of beta-arrestin 283 to GLP2R upon glucagon-like peptide 2 stimulation, but not with cAMP signalling, which suggests a 284 potential role for impaired beta-arrestin recruitment to GLP2R in the pathophysiology of type 2 285 diabetes ( Fig. 5D-F 
304
Serine and glycine levels play a critical role in the aetiology of a rare eye disease 305 A recent GWAS of macular telangiectasia type 2 (MacTel), a rare neurovascular degenerative 306 retinal disease, identified three genome-wide susceptibility loci (PHGDH, CPS1, and TMEM161B-307 LINC00461) of which the same variants at PHGDH and CPS1 were associated with levels of the amino 308 acids serine and glycine in this GWAS 21 . More recently, it was shown that low serine availability is 309 11 linked to both MacTel as well as hereditary sensory and autonomic neuropathy type 1 through 310 elevated levels of atypical deoxyshingolipids 22 . Whether genetic predisposition to low serine and 311 glycine levels affects MacTel more generally or has predictive utility has not been investigated. To 312 test this and to explore the specificity of associations between genetic influences on metabolite 313 levels and the risk of MacTel, we generated genetic risk scores (GRS) using the sentinel variants for 314 each of the 141 metabolites with at least one significantly associated locus identified in this GWAS 315 and tested their associations with the risk of MacTel. GRS's for serine and glycine were the only 316 scores associated with risk for MacTel after removal of the known highly pleiotropic GCKR variant 317 ( Fig. 6A) . Each standard deviation higher serine levels via the serine GRS was associated with a 95% 318 lower risk of MacTel (odds ratio (95% confidence interval), 0.05 (0.03-0.08); p=9.5×10 -30 ; Fig. 6A ).
319
Each of five serine associated variants was individually associated with lower MacTel risk, with a 320 clear dose-response relationship and no evidence of heterogeneity ( Fig. 6B) . The association was 321 unchanged when removing the GCKR locus. To disentangle the effect of these two highly correlated 322 metabolites on MacTel risk, we used multivariable Mendelian randomization analysis, which allowed 323 us to test for a causal effect of both measures simultaneously. In this analysis, the effect of serine 324 remained strong, while the effect of glycine was attenuated (Tab. 1). Glycine and serine can be 325 interconverted and these results provide genetic evidence that the link between glycine and MacTel 326 is via serine levels through glycine conversion. This hypothesis is supported by the evidence of a log-327 linear relationship between associations with serine and risk of MacTel among glycine-associated 328 variants ( Fig. 6B) . These findings provide strong evidence that pathways indexed by genetically 329 higher serine levels are strongly and causally associated with protection against MacTel.
330
Given the large observed effect size, we estimated whether using serine and glycine-associated rare extreme metabolic disorders that currently lack a genetic basis ( Fig. 7A) . In this study, there 357 were 153 locus-metabolite associations for which 53 unique IEM-associated genes were prioritized 358 as likely causal using either the hypothesis-free genetic approach or the knowledge-based approach 359 on the basis of the Orphanet database 24 . In 89% of these associations (136 of 153) the metabolite 360 associated with a given GWAS locus perfectly matched, or was closely related to, the metabolite 361 affected in patients with the corresponding IEM ( Fig. 7B) .
362
To test whether IEM-mirroring lead variants from our metabolite GWAS may increase the risk of 
396
This large-scale genome-wide meta-analysis has integrated genetic associations for 174 397 metabolites across different measurement platforms, an approach that has resulted in a three-fold 398 increase in our knowledge of genetic loci regulating levels of these metabolites. We assign likely 399 15 causal genes for many of the identified associations using a dual approach that combined automated 400 database mining with manual curation.
401
Previous platform-specific genetic studies of blood metabolites have been substantially smaller 402 in size due to being restricted to a single platform and/ or study 2,3,4,5,6,7,8 . We build on these earlier 403 studies to identify and demonstrate enrichment of rare and low-frequency coding variants in 404 enzyme and transporter genes with large effects and reveal the importance of non-linear 405 associations at several loci.
406
Our results not only provide detailed insight into the genetic determinants of human 407 metabolism but consider their relevance for disease aetiology and prediction. We explore both 408 locus-specific and polygenic score effects and provide tangible examples with clear translational 409 potential. We discovered a strong link between GLP2R, citrulline metabolism and type 2 diabetes, 410 and demonstrate that the p.Asp470Asn variant underlying the citrulline and diabetes associations 411 leads to significantly reduced recruitment of beta-arrestin to GLP2R in various cellular models.
412
GLP2R is related to GLP1R, a target of glucose-lowering therapeutic agonists approved for type 2 413 diabetes that mimic the other proglucagon gene encoded peptide glucagon-like peptide 1.
414
The finding that a standard deviation increase in serine levels via a genetic risk score is 415 associated with 95% lower risk of MacTel shows that genetic differences resulting in very specific 
438
To maximise sample size and power, we meta-analysed genome-wide association (GWAS) 
443
Metabolon platforms and 126 were unique to Biocrates (Fig. 1) . We integrated publicly available 444 summary statistics from genome-wide meta-analyses of the same metabolites measured using MS
445
(with Biocrates or Metabolon platforms) or 1 H-NMR spectrometry ( Supplementary Table 1 ).
446
Metabolites were matched across platforms by comparing metabolite names and biochemical 
449
Scientists at Metabolon Inc. independently reviewed and confirmed metabolite matches.
450
A summary of the characteristics of participating cohorts is given in Supplemental Table S1 . The
451
Fenland study is a population-based cohort study of 12,435 participants without diabetes born 
500
The levels of 10 metabolites were measured in the INTERVAL study using 1 H-NMR . Participants with >30% of metabolite measures missing and duplicated individuals were 507 removed. Metabolite data more than 10 SD from the mean was also removed.
508
GWAS and meta-analysis
509
In Fenland and EPIC-Norfolk, metabolite levels were natural log-transformed, winsorised to 510 five standard deviations and then standardised to a mean of 0 and a standard deviation of 1.
511
Genotypes were measured using Affymetrix Axiom or Affymetrix SNP5.0 genotyping arrays. In brief, 512 genotyping in Fenland was done in two waves including 1,500 (Affymetrix SNP5.0) and 9,369 513 (Affymetrix Axiom) participants (Supplemental table S1) and imputation was done using IMPUTE2 to 514 1000 Genomes Phase 1v3 (Affymetrix SNP5.0) or phase 3 (Affymetrix Axiom) reference panels
515
( Supplemental table S1 ). In EPIC-Norfolk, 21,044 samples were forwarded to imputation using 1000
516
Genomes Phase 3 (Oct. 2014) reference panels ( Supplemental table S1 ). Imputed SNPs with 517 imputation quality score less than 0.3 or minor allele account less than 2 were removed from the 518 imputed dataset. Genome-wide association analyses were carried out using BOLT-LMM v2.2 519 adjusting for age, sex, and study-specific covariates in mixed linear models. Alternatively (when the 
524
In INTERVAL, genotyping was conducting using the Affymetrix Axiom genotyping array.
525
Standard quality control procedures were conducted prior to imputation. 
536
For all GWAS analysis within Fenland, EPIC-Norfolk and INTERVAL, variants with Hardy-
537
Weinberg equilibrium p<1⨯10 -6 and associations with absolute value of effect size >5 or standard 538 error (SE) >10 or <0 were excluded; insertions and deletions were excluded.
539
For each metabolite, we performed a meta-analysis of z-scores (betas divided by standard 
577
We tested at each locus for conditional independent variants using exact stepwise conditional To assign likely causal genes to lead SNPs at each locus we generated a scoring system. We Odds ratio per SD increase 0.06 (0.03; 0.13) 0.10 (0.05; 0.21) p-value 9.45x10 -12 2.95x10 -9 Glycine (15 SNPs)
Odds ratio per SD increase 0.17 (0.08; 0.37) 0.50 (0.29; 0.87) p-value 9.99x10 -6 1.35x10 -2 MR estimates are based on the inverse variance-weighted method using random effects to pool 
